1. Home
  2. ARCC vs HALO Comparison

ARCC vs HALO Comparison

Compare ARCC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Capital Corporation

ARCC

Ares Capital Corporation

SELL

Current Price

$18.57

Market Cap

14.4B

Sector

Finance

ML Signal

SELL

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

SELL

Current Price

$110.91

Market Cap

12.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ARCC
HALO
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
12.0B
IPO Year
2004
2001

Fundamental Metrics

Financial Performance
Metric
ARCC
HALO
Price
$18.57
$110.91
Analyst Decision
Buy
Buy
Analyst Count
14
9
Target Price
$20.77
★ $101.75
AVG Volume (30 Days)
★ 4.4M
2.4M
Earning Date
10-27-2026
11-02-2026
Dividend Yield
★ 10.35%
N/A
EPS Growth
★ N/A
N/A
EPS
0.36
★ 3.11
Revenue
N/A
★ $151,862,000.00
Revenue This Year
$1.40
$33.93
Revenue Next Year
$3.06
$10.74
P/E Ratio
$51.47
★ $35.78
Revenue Growth
N/A
N/A
52 Week Low
$17.40
$61.23
52 Week High
$21.14
$116.85

Technical Indicators

Market Signals
Indicator
ARCC
HALO
Relative Strength Index (RSI) 36.30 54.77
Support Level $18.38 $105.27
Resistance Level $19.35 $111.15
Average True Range (ATR) 0.27 3.05
MACD -0.06 -0.55
Stochastic Oscillator 24.89 41.43

Price Performance

Historical Comparison
ARCC
HALO

About ARCC Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: